Alpine Immune Sciences, Inc. (NASDAQ:ALPN) Receives $50.33 Consensus Target Price from Analysts

Alpine Immune Sciences, Inc. (NASDAQ:ALPN) has received a consensus rating of “Hold” from the eleven analysts that are presently covering the company, Marketbeat.com reports. Eight research analysts have rated the stock with a hold recommendation and three have given a buy recommendation to the company. The average twelve-month price objective among brokerages that have updated their coverage on the stock in the last year is $50.33.

A number of research analysts recently issued reports on the stock. Leerink Partnrs cut shares of Alpine Immune Sciences from an “outperform” rating to a “market perform” rating in a research report on Thursday, April 11th. Wedbush cut shares of Alpine Immune Sciences from an “outperform” rating to a “neutral” rating in a research report on Thursday, April 11th. SVB Leerink cut shares of Alpine Immune Sciences from an “outperform” rating to a “market perform” rating and lifted their price target for the company from $42.00 to $65.00 in a research report on Friday, April 12th. Morgan Stanley reaffirmed an “equal weight” rating and issued a $65.00 target price (up from $47.00) on shares of Alpine Immune Sciences in a report on Thursday, April 11th. Finally, Guggenheim began coverage on shares of Alpine Immune Sciences in a report on Tuesday, April 9th. They issued a “buy” rating and a $55.00 target price for the company.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in ALPN. Allspring Global Investments Holdings LLC raised its holdings in shares of Alpine Immune Sciences by 745.5% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 1,488 shares of the biotechnology company’s stock valued at $28,000 after purchasing an additional 1,312 shares during the last quarter. AJOVista LLC purchased a new position in shares of Alpine Immune Sciences during the fourth quarter valued at approximately $64,000. Barclays PLC raised its holdings in shares of Alpine Immune Sciences by 44.3% during the third quarter. Barclays PLC now owns 9,126 shares of the biotechnology company’s stock valued at $104,000 after purchasing an additional 2,801 shares during the last quarter. Tower Research Capital LLC TRC raised its holdings in shares of Alpine Immune Sciences by 411.6% during the fourth quarter. Tower Research Capital LLC TRC now owns 5,490 shares of the biotechnology company’s stock valued at $105,000 after purchasing an additional 4,417 shares during the last quarter. Finally, New York State Common Retirement Fund raised its holdings in shares of Alpine Immune Sciences by 75.8% during the third quarter. New York State Common Retirement Fund now owns 9,634 shares of the biotechnology company’s stock valued at $110,000 after purchasing an additional 4,155 shares during the last quarter. 75.17% of the stock is owned by hedge funds and other institutional investors.

Alpine Immune Sciences Trading Up 0.1 %

Shares of ALPN opened at $64.62 on Friday. The firm’s 50-day moving average price is $42.90 and its 200-day moving average price is $26.26. The firm has a market capitalization of $4.24 billion, a price-to-earnings ratio of -100.97 and a beta of 1.14. Alpine Immune Sciences has a 1-year low of $6.71 and a 1-year high of $64.70.

Alpine Immune Sciences (NASDAQ:ALPN) last announced its earnings results on Monday, March 18th. The biotechnology company reported $0.15 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.32) by $0.47. Alpine Immune Sciences had a negative net margin of 54.66% and a negative return on equity of 15.54%. The firm had revenue of $30.85 million for the quarter, compared to analyst estimates of $6.90 million. On average, research analysts forecast that Alpine Immune Sciences will post -1.74 EPS for the current fiscal year.

About Alpine Immune Sciences

Alpine Immune Sciences, Inc operates as a clinical-stage biopharmaceutical company. It focuses on the discovery and development of immunotherapies through protein engineering technologies for treating autoimmune and inflammatory diseases. The company's product pipeline includes Povetacicept, a dual B cell cytokine antagonist, which is in Phase 2 clinical trial for the treatment of multiple autoimmune and inflammatory diseases; and Acazicolcept, a dual inhibitor of the CD28 and ICOS T cell costimulatory pathways that is in preclinical trial for the treatment of systemic lupus erythematosus.